All News
Does BASDAI work for women?
When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do our activity measures truly represent disease? Are there some measures best suited to different populations? Does BASDAI work for women?
Read Article
ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs
New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).
Read Article
Update: axSpA Recommendations
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR recommendations for axSpA were first developed in 2006, and last updated in 2016.
Read Article
ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment
On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.
Read Article
Video Telehealth Willingness Increased During Pandemic
Americans’ willingness to use video telehealth has increased since the beginning of the COVID-19 pandemic, rising most sharply among Black Americans and people with less education, according to a new RAND Corporation study.
Read Article
Opportunistic Infections with JAK inhibitors in RA
Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials, althou
Read Article
2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections
A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).
Read Article
Women with Rheumatic Disease (11.4.2022)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Read Article
Undiagnosed RA During the Pandemic
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
Read Article
SLE T2T - Lupus Low Disease Activity State Predicts Outcomes
Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.
Read Article
2022 CDC Clinical Practice Guideline on Opioid Prescribing
The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.
Read Article
ACR Promotes CME on Lupus Clinical Trials Racial Disparities
The American College of Rheumatology (ACR) has released Continuing Medical Education (CME) for dermatologists and nephrologists to help them learn more about clinical trials for lupus patients in their respective treatment areas and the importance of getting more of their African American/Black p
Read Article
Can You Withdraw Ixekizumab in Stable Axial Spondyloarthritis?
Remission often invites consideration of drug withdrawal in patients with axial spondyloarthritis (axSpA).
Read Article
Excessive Alcohol-Related Deaths in US Adults
Alcohol consumption is a leading preventable cause of death in the U.S. A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49.
Read Article
EMA Crack Down on JAK Inhibitors
The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.
Read Article
Infections & Lupus (10.28.2022)
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Read Article
Infection: a Leading Cause of Death in Lupus
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
Read Article
Update to Axial Spondyloarthritis Guidance
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
Read Article
New ACR/EULAR Guideline Expands RA Remission Definition
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
Read Article
Increasing Prevalence of RA, PsA and AS in the UK
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.
Read Article
